DC-SX029

DC-SX029 is a potent SNX10 protein-protein interaction (PPI) inhibitor with oral activity with an estimated KD constant of ~0.935 μM by surface plasmon resonance (SPR) . DC-SX029 blocks the SNX10-PIKfyve interaction, thereby decreased the TBK1/c-Rel signaling activation. DC-SX029 does not affect the protein level of SNX10. DC-SX029 has the potential for inflammatory bowel disease (IBD) research[1][2].

Product Specifications

CAS Number

[300713-88-6]

UNSPSC

12352005

Target

IKK; NF-κB; PIKfyve

Type

Reference compound

Related Pathways

NF-κB; PI3K/Akt/mTOR

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/dc-sx029.html

Purity

98.07

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C(NC1=CC=C(S(=O)(NCC(C(F)(F)F)CCC(O)=O)=O)C=C1)OC

Molecular Formula

C14H17F3N2O6S

Molecular Weight

398.35

References & Citations

[1]Weilian Bao, et al. Targeting sorting nexin 10 improves mouse colitis via inhibiting PIKfyve-mediated TBK1/c-Rel signaling activation. Pharmacol Res. 2021 Jul:169:105679.|[2]Weilian Bao, et al. Inhibiting sorting nexin 10 promotes mucosal healing through SREBP2-mediated stemness restoration of intestinal stem cells. Sci Adv. 2023 Sep;9 (35) :eadh5016.